Dr Lunning is Assistant Professor in the Department of Internal Medicine and has been a faculty member at the University of Nebraska Medical Center since 2013. After pursuing his medical training at Des Moines University College of Osteopathic Medicine, he completed his internal medicine residency at the University of Nebraska Medical Center, including serving a year as Chief Resident. Dr Lunning then completed his hematology/oncology fellowship at Memorial Sloan-Kettering Cancer Center in New York, NY. Returning to Omaha, he used his expertise in such hematologic malignancies as non-Hodgkin’s lymphoma and multiple myeloma, working with the Transplant Center at UNMC and presenting results of his research at major association meetings. He has authored many articles on T-cell lymphomas, B-cell lymphoma, mantle cell lymphoma, acute lymphoblastic leukemia, as well as on the side effects of chemotherapy. They have appeared in leading journals such as the American Journal of Clinical Oncology, Blood, Leukemia and Lymphoma, and the British Journal of Haematology. Dr Lunning is actively involved in clinical research, participating in the National Comprehensive Cancer Network’s programs, as well as serving as a member of the graduate student faculty.
Dr Freifeld is a professor of infectious diseases and medicine at the University of Nebraska Medical Center where, over the last 12 years, she has implemented programs in management of infectious complications in cancer and solid organ transplant patients. Her career focus over the last 20-plus years has been to understand the best management of fever and neutropenia in cancer patients. Recently, she chaired the IDSA national clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer, which has brought forth a more standardized framework for approaching these complex and vulnerable patients. She also has chaired and currently sits on the NCCN guideline committee for management of infections in cancer patients.
Dr Freifeld attended medical school and undertook her internal medicine residency at the Johns Hopkins School of Medicine and the Johns Hopkins Hospital, respectively; completed basic internal medicine training in 1985; and went on pursue her fellowship training in infectious diseases at the National Institute of Allergy and Infectious Diseases in Bethesda, MD. She became director of the infectious diseases group for the National Cancer Institute from 1990 until 1999. At NCI, she developed theories about the use of oral antibiotics to treat low-risk fever and neutropenia, leading to the current broad use of oral and/or outpatient antibiotics in this setting. In 2000, Dr Freifeld moved to the University of Nebraska Medical Center to initiate programs in immunocompromised host infectious diseases. She has since published many chapters, papers, and editorials on this topic of health care.
Dr Lewis is the ID Clinical Pharmacy Coordinator at Oregon Health and Science University in Portland, Oregon. Previously, Dr Lewis was Clinical Associate Professor in the Department of Medicine, Division of Infectious Diseases, at the University of Texas Health Science Center, where he also served as the Infectious Diseases Program Manager and Co-director of the PGY-2 Infectious Diseases Residency Program.
Dr Lewis earned his Bachelor of Pharmacy degree and Doctorate in Pharmacy from Washington State University. He then completed a pharmacy practice residency at Southwest Washington Medical Center in Vancouver, Washington, followed by a specialty residency in infectious diseases pharmacotherapy in a combined program at the University of Texas Health Sciences Center at San Antonio and South Texas Veterans Health Care System.
Dr Lewis has been published in several journals, including Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy, and Journal of Clinical Microbiology. He serves as a reviewer for various publications, including Clinical Infectious Diseases, Antimicrobial Agents and Chemotherapy, and Journal of Antimicrobial Chemotherapy. His current research focus is on fungal and bacterial infections and therapy. Dr Lewis also has extensive experience in formulary management and cost-containment measures in the hospital setting. He currently serves as the Co-Chair of the CLSI Breakpoint Working Group and, since 2011, has been a fellow of the Infectious Diseases Society of America.
Dr Maertens is currently Associate Professor of Hematology, Department of Hematology, Universitaire Ziekenhuizen Leuven, campus Gasthuisberg. He received his medical degree from the Catholic University of Leuven, Belgium. He completed an internal medicine residency and clinical hematology fellowship at the University Hospital, Leuven. Dr Maertens is a member of the Immunocompromised Host Society, the International Society of Human and Animal Mycology, the Belgian Infectious Diseases Advisory Board, the Multinational Association of Supportive Care in Cancer, the American Society of Hematology, the European Group for Blood and Marrow Transplantation, among other organizations. He served as chair of the European Organization for Research and Treatment of Cancer (EORTC)-Infectious Diseases Group and is one of the steering committee members for the European Conference on Infections in Leukaemia (ECIL) meetings.
Dr Maertens’s main academic interests are allogeneic stem cell and bone marrow transplantation for hematologic and autoimmune disease and treatment of acute myeloid leukemia and acute lymphoblastic leukemia, as well as supportive care for immunocompromised patients, with special emphasis on treatment of invasive fungal infections. He has published articles on management and diagnosis of fungal infections in several esteemed journals, including the New England Journal of Medicine, Blood, Cancer, Mycoses, and Bone Marrow Transplantation. In addition, he co-edited, with Dr Kieren Marr, the monograph, Diagnosis of Fungal Infections. He also serves as transplant registry coordinator for the Belgian Hematological Society.
Dr Bow is Professor of the Departments of Internal Medicine and Medical Microbiology and Infectious Diseases at the University of Manitoba, Winnipeg, and Member in the Sections of Infectious Diseases and Hematology/Oncology in the Department of Internal Medicine, University of Manitoba. He is Director, Infection Control Services, at CancerCare Manitoba and is a consultant in Infectious Diseases and Hematology/Oncology in the Winnipeg Regional Health Authority. He is an attending physician in the Manitoba Blood and Marrow Transplant Programme based at the Health Sciences Centre, Winnipeg, and at CancerCare Manitoba. In addition, he is Attending Physician in Hematology/Oncology at St. Boniface General Hospital and Health Sciences Centre, Attending Physician in Hematology/Oncology at the Health Sciences Centre, and Attending Physician in Infectious Diseases at the St. Boniface General Hospital and Health Sciences Centre.
Dr Bow graduated from the University of Calgary, and trained in General Internal Medicine, Hematology and Oncology at McMaster University, in Clinical Microbiology at the University of Toronto, and in Infectious Diseases at the University of Manitoba. From June 2009 to November 2012, Dr Bow held the position of Medical Director of the Oncology Programme at the Winnipeg Regional Health Authority. From 1997 to June 2009, he held the positions of Head of the Section of Hematology/Oncology at the University of Manitoba, Health Sciences Centre, and St. Boniface General Hospital; and Head of the Department of Medical Oncology and Hematology at CancerCare Manitoba; also, the position of Director and Chief of Services at the GD6 Oncology Unit in the Health Sciences Centre, Oncology Program, Winnipeg Regional Health Authority from 1990 to June 2009. Dr Bow was the recipient three times of the Clinical Infectious Diseases Award for Outstanding Review. He has published widely and has authored several book chapters.
He is currently a member of several Clinical Practice Guidelines panels, including the Infectious Diseases Society of America, American Society of Clinical Oncology, the Centers for Disease Control and Prevention, and the Association for Medical Microbiology and Infectious Diseases Canada. He is a member of the Steering Committee for the International Mycoses Study Group; a member of the Multinational Association for Supportive Care in Cancer, Mucositis Study Group; and has been a member of Council for the International Immunocompromised Host Society. He is also a member of several professional societies, and a manuscript reviewer on numerous peer-reviewed journals. Dr Bow’s research interests have focused on the prevention and management of bacterial and fungal infections in neutropenic cancer patients and cytotoxic therapy-induced intestinal epithelial damage in the pathogenesis of these infections.